MANAGEMENT BIOS
|
Hojuhn Song, Ph.D.
Co-Founder and Chief Executive Officer Hojuhn is a biopharmaceutical leader and executive who has successfully led several R&D teams in start-up, and global large-pharmaceutical settings. His teams have progressed multiple novel agents through development in oncology, immune disorder, and neurodegeneration.
Before founding Pinetree Therapeutics, Inc, Hojuhn was a project team leader for novel target discovery in Functional Genomics and Developmental Molecular Pathway at Novartis Institute for Biomedical Research and successfully generated multiple clinical candidates in multiple therapeutic areas. Hojuhn earned a Ph.D. in Genetics and Neurobiology at Oregon State University and completed a post-doctoral fellowship at Novartis AG. He received M.S in Genetics and a B.Sc. In Biology from Chungnam National University, S. Korea. |
|
Paul Rennert
Member, SAB Paul is a top-tier Biotechnology Investigator and Executive with extensive strategic and leadership experience. He has demonstrated success from bench to bedside developing small molecules and biologics for oncology, autoimmunity, chronic inflammation and fibrosis.
Starting his outstanding career at Repligen and Biogen, Paul has an excellent track record of developing drugs, supported by multiple drug development campaigns with success, over 40 patents granted, and approximately 100 peer-reviewed publications. He is currently serving as President and CSO at Aleta Biotherapeutics and has been working together with Pinetree for many months as a consultant. |
|
Josh Blacher, MBA
CFO Mr. Blacher has served in senior financial leadership roles for 25+ years and is currently Managing Partner of Columbus Circle Capital, a strategic finance and corporate development advisory firm focused on the life sciences industry. Previously, he helped build and manage Teva Innovative Ventures, Teva Pharmaceuticals’ early-stage in-licensing and investment unit. Following his tenure at Teva, he served as CFO/CBO to three NASDAQ-traded biotechnology companies, the most recent of which was Inmed Pharmaceuticals. At Inmed, he championed and helped execute the company’s IPO, and managed its finance and accounting, business development and investor relations departments. Earlier in his career, he held senior positions in portfolio management at Deutsche Asset Management and equity research at Morgan Stanley, as well as in mergers & acquisitions at Lehman Brothers. He earned an MBA in Finance from Columbia Business School and BA in Economics from Yeshiva University.
|